Usefulness of CHADS2 and CHA2DS2-VASc Scores in the Prediction of New-Onset Atrial Fibrillation: A Population-Based Study

American Journal of Medicine

Volumn 129, Issue 8, 2016, Pages 843-849

  Saliba, Walid ^a   Gronich, Naomi ^a   Barnett Griness, Ofra ^a   Rennert, Gad ^a,b  

^a TECHNION ISRAEL INSTITUTE OF TECHNOLOGY   (Israel)

^b CLALIT HEALTH SERVICES   (Israel)

Author keywords

Atrial fibrillation; CHA2DS2 VASc score; CHADS2 score; Clinical prediction rule

Indexed keywords

ADULT; AGED; AREA UNDER THE CURVE; ARTICLE; CARDIOVASCULAR DISEASE ASSESSMENT; CHA2DS2 VASC SCORE; CHADS2 SCORE; CONTROLLED STUDY; FEMALE; FOLLOW UP; HAZARD RATIO; HUMAN; INCIDENCE; MAJOR CLINICAL STUDY; MALE; NEW-ONSET ATRIAL FIBRILLATION; PREVALENCE; PRIORITY JOURNAL; RISK FACTOR; ATRIAL FIBRILLATION; ISRAEL; MIDDLE AGED; PREDICTIVE VALUE; PROCEDURES; RISK ASSESSMENT;

AGED; ATRIAL FIBRILLATION; FEMALE; HUMANS; INCIDENCE; ISRAEL; MALE; MIDDLE AGED; PREDICTIVE VALUE OF TESTS; RISK ASSESSMENT; RISK FACTORS;

EID: 84964608100     PISSN: 00029343     EISSN: 15557162     Source Type: Journal    
DOI: 10.1016/j.amjmed.2016.02.029     Document Type: Article

References (28)

1. 1 Wolf, P.A., Abbott, R.D., Kannel, W.B., Atrial fibrillation: a major contributor to stroke in the elderly. The Framingham Study. Arch Intern Med 147 (1987), 1561–1564.
2. 2 Steger, C., Pratter, A., Martinek-Bregel, M., et al. Stroke patients with atrial fibrillation have a worse prognosis than patients without: data from the Austrian Stroke registry. Eur Heart J 25 (2004), 1734–1740.
3. 3 Mattle, H.P., Long-term outcome after stroke due to atrial fibrillation. Cerebrovasc Dis 16:suppl 1 (2003), 3–8.
4. 4 Lin, H.J., Wolf, P.A., Kelly-Hayes, M., et al. Stroke severity in atrial fibrillation. The Framingham Study. Stroke 27 (1996), 1760–1764.
5. 5 Gage, B.F., Waterman, A.D., Shannon, W., et al. Validation of clinical classification schemes for predicting stroke: results from the National Registry of Atrial Fibrillation. JAMA 285 (2001), 2864–2870.
6. 6 Lip, G.Y., Nieuwlaat, R., Pisters, R., et al. Refining clinical risk stratification for predicting stroke and thromboembolism in atrial fibrillation using a novel risk factor-based approach: the euro heart survey on atrial fibrillation. Chest 137 (2010), 263–272.
7. 7 Camm, A.J., Lip, G.Y., De Caterina, R., et al., ESC Committee for Practice Guidelines (CPG). 2012 focused update of the ESC Guidelines for the management of atrial fibrillation: an update of the 2010 ESC Guidelines for the management of atrial fibrillation. Developed with the special contribution of the European Heart Rhythm Association. Eur Heart J 33 (2012), 2719–2747.
8. 8 January, C.T., Wann, L.S., Alpert, J.S., et al., American College of Cardiology/American Heart Association Task Force on Practice Guidelines. 2014 AHA/ACC/HRS guideline for the management of patients with atrial fibrillation: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the Heart Rhythm Society. J Am Coll Cardiol 64 (2014), e1–e76.
9. 9 Schnabel, R.B., Sullivan, L.M., Levy, D., et al. Development of a risk score for atrial fibrillation (Framingham Heart Study): a community-based cohort study. Lancet 373 (2009), 739–745.
10. 10 Benjamin, E.J., Levy, D., Vaziri, S.M., et al. Independent risk factors for atrial fibrillation in a population-based cohort. The Framingham Heart Study. JAMA 271 (1994), 840–844.
11. 11 Wang, T.J., Larson, M.G., Levy, D., et al. Temporal relations of atrial fibrillation and congestive heart failure and their joint influence on mortality: the Framingham Heart Study. Circulation 107 (2003), 2920–2925.
12. 12 Saliba, W., Barnett-Griness, O., Elias, M., Rennert, G., Neutrophil to lymphocyte ratio and risk of a first episode of stroke in patients with atrial fibrillation: a cohort study. J Thromb Haemost 13 (2015), 1971–1979.
13. 13 Saliba, W., Barnett-Griness, O., Elias, M., Rennert, G., The association between red cell distribution width and stroke in patients with atrial fibrillation. Am J Med 128 (2015), 192.e11–192.e18.
14. 14 Healey, J.S., Connolly, S.J., Gold, M.R., et al., ASSERT Investigators. Subclinical atrial fibrillation and the risk of stroke. N Engl J Med 366 (2012), 120–129.
15. 15 Chao, T.F., Liu, C.J., Chen, S.J., et al. CHADS2 score and risk of new-onset atrial fibrillation: a nationwide cohort study in Taiwan. Int J Cardiol 168 (2013), 1360–1363.
16. 16 Mitchell, L.B., Southern, D.A., Galbraith, D., et al., APPROACH investigators. Prediction of stroke or TIA in patients without atrial fibrillation using CHADS2 and CHA2DS2-VASc scores. Heart 100 (2014), 1524–1530.
17. 17 Casaclang-Verzosa, G., Gersh, B.J., Tsang, T.S., Structural and functional remodeling of the left atrium: clinical and therapeutic implications for atrial fibrillation. J Am Coll Cardiol 51 (2008), 1–11.
18. 18 Li, Y., Ding, W., Wang, H., et al. Relationship of CHA2DS2-VASc and CHADS2 score to left atrial remodeling detected by velocity vector imaging in patients with atrial fibrillation. PLoS One, 8, 2013, e77653.
19. 19 Vaziri, S.M., Larson, M.G., Benjamin, E.J., Levy, D., Echocardiographic predictors of nonrheumatic atrial fibrillation. The Framingham Heart Study. Circulation 89 (1994), 724–730.
20. 20 Casaclang-Verzosa, G., Barnes, M.E., Blume, G., et al. C-reactive protein, left atrial volume, and atrial fibrillation: a prospective study in high-risk elderly. Echocardiography 27:4 (2010), 394–399.
21. 21 Chao, T.F., Cheng, C.C., Lin, W.S., et al. Associations among the CHADS(2) score, atrial substrate properties, and outcome of catheter ablation in patients with paroxysmal atrial fibrillation. Heart Rhythm 8 (2011), 1155–1159.
22. 22 Gladstone, D.J., Spring, M., Dorian, P., et al., EMBRACE Investigators and Coordinators. Atrial fibrillation in patients with cryptogenic stroke. N Engl J Med 370 (2014), 2467–2477.
23. 23 Sanna, T., Diener, H.C., Passman, R.S., et al., CRYSTAL AF Investigators. Cryptogenic stroke and underlying atrial fibrillation. N Engl J Med 370 (2014), 2478–2486.
24. 24 Heeringa, J., van der Kuip, D.A., Hofman, A., et al. Prevalence, incidence and lifetime risk of atrial fibrillation: the Rotterdam study. Eur Heart J 27 (2006), 949–953.
25. 25 Tse, H.F., Oral, H., Pelosi, F., et al. Effect of gender on atrial electrophysiologic changes induced by rapid atrial pacing and elevation of atrial pressure. J Cardiovasc Electrophysiol 12 (2001), 986–989.
26. 26 Veronesi, U., Maisonneuve, P., Rotmensz, N., et al., Italian Tamoxifen Study Group. Tamoxifen for the prevention of breast cancer: late results of the Italian Randomized Tamoxifen Prevention Trial among women with hysterectomy. J Natl Cancer Inst 99 (2007), 727–737.
27. 27 Bretler, D.M., Hansen, P.R., Lindhardsen, J., et al. Hormone replacement therapy and risk of new-onset atrial fibrillation after myocardial infarction—a nationwide cohort study. PLoS One, 7, 2012, e51580.
28. 28 Perez, M.V., Wang, P.J., Larson, J.C., et al. Effects of postmenopausal hormone therapy on incident atrial fibrillation: the Women's Health Initiative randomized controlled trials. Circ Arrhythm Electrophysiol 5:6 (2012), 1108–1116.